Objective: To investigate the prevalence and antibiotic susceptibility pattern of extended-spectrum β-lactamases (ESBL)-producing Enterobacteriaecae among patients in the United Arab Emirates. Materials and Methods: A total of 130 Enterobacteriaceaecomprising of Escherichia coli (n = 83), Klebsiella pneumoniae (n = 45) and Klebsiella oxytoca (n = 2) was studied. Of these 130 isolates, 64 were from urine. ESBL screening was by disc diffusion and confirmatory tests for ESBL phenotype were conducted using BD Phoenix™ ESBL System and cephalosporin/clavulanate combination discs. Susceptibility to a panel of antibiotics was evaluated. Results: Of the 130 isolates, 53 (41%) were identified as having ESBL phenotype; of these, 32 (60%) were E. coli, 20 (36%) K. pneumoniae and 2 (4%) K. oxytoca. ESBL phenotype was seen in 100% of endotracheal tubes isolates, 20 (31%) from urine, 7 (58%) from blood and 4 (80%) from catheter tips. Amikacin susceptibility was 100%. Over 90% of ESBL isolates showed resistance to aztreonam and cephalosporins. All Klebsiella isolates were carbapenem sensitive. One ESBL isolate showed intermediate resistance to imipenem and meropenem (both MIC 8 µg/ml), cefotetan (MIC 32 µg/ml) and piperacillin/tazobactam (MIC 32 µg/ml). MIC for the carbapenems was lower in non-ESBL isolates (0.034 µg/ml) than ESBL isolates (0.071 µg/ml). Resistance to gentamicin, ciprofloxacin and piperacillin/tazobactam was higher in ESBL than non-ESBL isolates (p < 0.05). Conclusion: A high prevalence of ESBL-producing bacteria exists among in-patients in the United Arab Emirates. Amikacin and carbapenems remain the most effective drugs, but the presence of carbapenem-resistant ESBL-producing E. coli and occurrence of multidrug resistance are of concern. Continued surveillance and judicious antibiotic usage are recommended.
Objective: To assess the susceptibility trends of community-acquired extended-spectrum β-Iactamase (ESBL)-producing urinary isolates with particular reference to fosfomycin, nitrofurantoin and tigecycline. Materials and Methods: Seven hospitals across the United Arab Emirates participated in this study from June 2008 to March 2010. The antibiotic sensitivity of ESBL-producing uropathogens to a panel of antibiotics including tigecycline, fosfomycin and nitrofurantoin was assessed. The Hyplex ESBL identification system (h-ES-ID) was used for genotypic identification. Results: Two hundred and ninety-two ESBL-producing Enterobacteriaceae isolates were identified during the study period. Of these, 182 (62%) were urinary isolates and comprised of Escherichia coli: 149 (81.9%), Klebsiella pneumoniae: 30 (16.5%) and Proteus mirabilis: 3 (1.6%). Of the 182 urinary isolates, 179 (98.3%) were from patients with community onset urinary tract infections. The h-ES-ID system identified 172 (94.5%) of the urinary isolates as CTX-M positive. All isolates were susceptible to imipenem and meropenem. Over half of the isolates showed resistance to gentamicin (98; 53.8%), trimethoprim-sulfamethoxazole (139; 76.4%) and ciprofloxacin (143; 78.6%). Sensitivity to nitrofurantoin and fosfomycin was 90 and 100%, respectively. Two CTX-M-positive K. pneumoniae isolates with tigecycline resistance (MIC >4 µg/ml) were identified. Conclusion: There is dissemination of CTX-M ESBL-producing urinary pathogens into the community. Fosfomycin and nitrofurantoin were active against ESBL-positive uropathogens, and emergence of tigecycline resistance needs close monitoring.
Objective: To describe the spectrum of etiologic agents causing community associated UTI and their antimicrobial resistance trends in a large teaching hospital in Sharjah, United Arab Emirates.
Methods:A retrospective review of the microbiology laboratory records of four hundred ninety two cases of community associated UTI between April 2006 and March 2007 was carried out. Etiologic agents and their antimicrobial susceptibility pattern were analyzed.Results: A wide spectrum of uropathogens was isolated of which the leading etiologic agents of community associated UTI were Escherichia coli (207 strains) and Klebsiella species (90 strains). Sixty-six per cent of Gram-negative bacilli were resistant to amoxicillin, 58.5% were resistant to trimethoprim-sulfamethoxazole and more than 50% were resistant to cephalexin. However, resistance rate to antimicrobials like ciprofl oxacin and ceftriaxone remain relatively low 9.7% and 7.6% respectively.
Conclusions:Escherichia coli remains the leading cause of community associated UTI. In-vitro antimicrobial resistance pattern of the isolates revealed that trimethoprim-sulfamethoxazole, cephalexin and amoxycillin the commonly used fi rstline antimicrobials were becoming less and less effective in their treatment. This information can help in changing preferences of suitable antimicrobial agent in treatment of community associated UTI.
Objective: To describe the misidentification of Brucella melitensis as Bergeyella zoohelcum by MicroScan WalkAway®, a commonly used bacterial identification system. Clinical Presentation and Intervention: A 35-year-old man was admitted to the Intensive Care Unit with sepsis syndrome. Three sets of aerobic blood culture samples were positive after 48 h of incubation. The isolated organism was identified as B. zoohelcum using the MicroScan WalkAway (Siemens Healthcare Diagnostics Inc., West Sacramento, Calif., USA). However, due to the rareness of the pathogen, the isolate was reidentified as B. melitensis with Vitek® 2 system and later 16S ribosomal sequence analysis confirmed the isolate as B. melitensis having 100% match. Conclusion: This case showed that Brucella can be misidentified using MicroScan WalkAway. Countries where brucellosis is endemic need to be careful while using such automated identification systems in order not to miss the diagnosis of Brucella.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.